SentrySciences, a full-service system integrator and instrument distributor, has announced that it will be relocating the company from its current location in the Prospect Downtown area to 1551 South Sunset Street, Suite B, Longmont, CO 80501.
The Colorado-based company specialises in instrumentation designed to help manufacturers detect, identify and control contamination in their manufacturing processes and environments. With a range of technologies designed to detect airborne total and viable particulate, foreign object debris (FOD), large particles on surfaces, and rapid microbial methods for microbial detection, SentrySciences provides solutions for manufacturers faced with tough micro-contamination problems.
As part of the evolution of SentrySciences, having a space that is specifically designed and tailored to our needs will certainly improve our productivity and performance
Erik Haugen, COO of SentrySciences, said: "We are excited to be able to consolidate to a more functional space, which provides easier access to our suppliers, customers, and employees, and allows us to better integrate workflows, improve our overall efficiency, and increase opportunities for collaboration."
CEO Glenn Brandon added: "As part of the evolution of SentrySciences, having a space that is specifically designed and tailored to our needs will certainly improve our productivity and performance, but will also drive us to be the company that we are convinced we can be. It establishes a tone for today and provides the necessary resources for growth going forward."
In June 2021, SentrySciences announced the development of ParticleSentry AI. This revolutionary new product combines deep machine learning and computational statistics to characterise protein aggregates and subvisible particles in biologic drug products. Since then, the team at SentrySciences has been working on software and infrastructure to support the full market release of this novel product.
ParticleSentry AI first-generation software is optimised for automated processing of FlowCam flow imaging microscopy (FIM) images. The US Pharmacopeia has recognised FIM as an orthogonal method to light obscuration to identify and quantify subvisible particulate for some time. Using archived orthogonal FIM images (or new images), the new software develops a fingerprint of a biologic drug. The fingerprints are quantitatively compared to other image sets to support drug candidate developability, stress and accelerated stability testing.